The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma

被引：244

作者：

Berry, Teeara ^{[1
,2
]}

Luther, William ^{[4
]}

Bhatnagar, Namrata ^{[4
]}

Jamin, Yann ^{[3
]}

Poon, Evon ^{[1
,2
]}

Sanda, Takaomi ^{[4
]}

Pei, Desheng ^{[4
]}

Sharma, Bandana ^{[4
]}

Vetharoy, Winston R. ^{[1
,2
]}

Hallsworth, Albert ^{[1
,2
]}

Ahmad, Zai ^{[1
,2
]}

Barker, Karen ^{[1
,2
]}

Moreau, Lisa ^{[4
]}

Webber, Hannah ^{[1
,2
]}

Wang, Wenchao ^{[4
]}

Liu, Qingsong ^{[5
]}

Perez-Atayde, Antonio ^{[7
]}

Rodig, Scott ^{[6
]}

Cheung, Nai-Kong ^{[8
]}

Raynaud, Florence ^{[1
,2
]}

Hallberg, Bengt ^{[9
]}

Robinson, Simon P. ^{[3
]}

Gray, Nathanael S. ^{[5
]}

Pearson, Andrew D. J. ^{[1
,2
,10
]}

Eccles, Suzanne A. ^{[1
,2
]}

Chesler, Louis ^{[1
,2
,10
]}

George, Rani E. ^{[4
]}

机构：

[1] Inst Canc Res, Div Clin Studies, Surrey SM2 5NG, England

[2] Inst Canc Res, Div Canc Therapeut, Surrey SM2 5NG, England

[3] Inst Canc Res, Div Radiotherapy & Imaging, Surrey SM2 5NG, England

[4] Harvard Univ, Sch Med, Dana Farber Canc Inst & Childrens Hosp Boston, Dept Pediat Hematol & Oncol, Boston, MA 02115 USA

[5] Harvard Univ, Sch Med, Dana Farber Canc Inst & Biol Chem & Mol Pharmacol, Dept Canc Biol, Boston, MA 02115 USA

[6] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA

[7] Childrens Hosp, Dept Pathol, Boston, MA 02115 USA

[8] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10065 USA

[9] Umea Univ, Dept Mol Biol, Umea, Sweden

[10] Royal Marsden NHS Trust, Children & Young Peoples Unit, Surrey SM2 5PT, England

来源：

CANCER CELL | 2012年 / 22卷 / 01期

基金：

英国惠康基金; 美国国家卫生研究院; 英国医学研究理事会; 英国工程与自然科学研究理事会;

关键词：

ANAPLASTIC LYMPHOMA KINASE; N-MYC; ALK KINASE; C-MYC; ACTIVATING MUTATIONS; EXPRESSION; PHOSPHORYLATION; PROGRESSION; INHIBITION; RESISTANCE;

D O I：

10.1016/j.ccr.2012.06.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The ALK(F1174L) mutation is associated with intrinsic and acquired resistance to crizotinib and cosegregates with MYCN in neuroblastoma. In this study, we generated a mouse model overexpressing ALK(F1174L) in the neural crest. Compared to ALKF1174L and MYCN alone, co-expression of these two oncogenes led to the development of neuroblastomas with earlier onset, higher penetrance, and enhanced lethality. ALK(F1174L)/MYCN tumors exhibited increased MYCN dosage due to ALK(F1174L)-induced activation of the PI3K/AKT/mTOR and MAPK pathways, coupled with suppression of MYCN pro-apoptotic effects. Combined treatment with the ATP-competitive mTOR inhibitor Torin2 overcame the resistance of ALK(F1174L)/MYCN tumors to crizotinib. Our findings demonstrate a pathogenic role for ALK(F1174L) in neuroblastomas overexpressing MYCN and suggest a strategy for improving targeted therapy for ALK-positive neuroblastoma.

引用

页码：117 / 130

页数：14

共 44 条

[1] Conditional transgenic models define how MYC initiates and maintains tumorigenesis [J].

Arvanitis, Constadina ;

Felsher, Dean W. .

SEMINARS IN CANCER BIOLOGY, 2006, 16 (04) :313-317

[2]

BANERJEE SA, 1992, J NEUROSCI, V12, P4460

[3] Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma [J].

Bresler, Scott C. ;

Wood, Andrew C. ;

Haglund, Elizabeth A. ;

Courtright, Joshua ;

Belcastro, Lili T. ;

Plegaria, Jefferson S. ;

Cole, Kristina ;

Toporovskaya, Yana ;

Zhao, Huaqing ;

Carpenter, Erica L. ;

Christensen, James G. ;

Maris, John M. ;

Lemmon, Mark A. ;

Mosse, Yael P. .

SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (108)

[4] AMPLIFICATION OF N-MYC IN UNTREATED HUMAN NEUROBLASTOMAS CORRELATES WITH ADVANCED DISEASE STAGE [J].

BRODEUR, GM ;

SEEGER, RC ;

SCHWAB, M ;

VARMUS, HE ;

BISHOP, JM .

SCIENCE, 1984, 224 (4653) :1121-1124

[5] Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor [J].

Butrynski, James E. ;

D'Adamo, David R. ;

Hornick, Jason L. ;

Dal Cin, Paola ;

Antonescu, Cristina R. ;

Jhanwar, Suresh C. ;

Ladanyi, Marc ;

Capelletti, Marzia ;

Rodig, Scott J. ;

Ramaiya, Nikhil ;

Kwak, Eunice L. ;

Clark, Jeffrey W. ;

Wilner, Keith D. ;

Christensen, James G. ;

Jaenne, Pasi A. ;

Maki, Robert G. ;

Demetri, George D. ;

Shapiro, Geoffrey I. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18) :1727-1733

[6] Paracrine Signaling Through MYCN Enhances Tumor-Vascular Interactions in Neuroblastoma [J].

Chanthery, Yvan H. ;

Gustafson, W. Clay ;

Itsara, Melissa ;

Persson, Anders ;

Hackett, Christopher S. ;

Grimmer, Matt ;

Charron, Elise ;

Yakovenko, Slava ;

Kim, Grace ;

Matthay, Katherine K. ;

Weiss, William A. .

SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (115)

[7] Oncogenic mutations of ALK kinase in neuroblastoma [J].

Chen, Yuyan ;

Takita, Junko ;

Choi, Young Lim ;

Kato, Motohiro ;

Ohira, Miki ;

Sanada, Masashi ;

Wang, Lili ;

Soda, Manabu ;

Kikuchi, Akira ;

Igarashi, Takashi ;

Nakagawara, Akira ;

Hayashi, Yasuhide ;

Mano, Hiroyuki ;

Ogawa, Seishi .

NATURE, 2008, 455 (7215) :971-U56

[8] Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma [J].

Chesler, Louis ;

Schlieve, Chris ;

Goldenberg, David D. ;

Kenney, Anna ;

Kim, Grace ;

McMillan, Alex ;

Matthay, Katherine K. ;

Rowitch, David ;

Weiss, William A. .

CANCER RESEARCH, 2006, 66 (16) :8139-8146

[9] The anaplastic lymphoma kinase in the pathogenesis of cancer [J].

Chiarle, Roberto ;

Voena, Claudia ;

Ambrogio, Chiara ;

Piva, Roberto ;

Inghirami, Giorgio .

NATURE REVIEWS CANCER, 2008, 8 (01) :11-23

[10] Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma [J].

Christensen, James G. ;

Zou, Helen Y. ;

Arango, Maria E. ;

Li, Qiuhua ;

Lee, Joseph H. ;

McDonnell, Scott R. ;

Yamazaki, Shinji ;

Alton, Gordon R. ;

Mroczkowski, Barbara ;

Los, Gerrit .

MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) :3314-3322

← 1 2 3 4 5 →